OncoMatch/Clinical Trials/NCT06563986
FTD-TPI, Bevacizumab, and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer
Is NCT06563986 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Systemic treatment (FTD-TPI and bevacizumab) and Radioembolization with 166-Ho microspheres for metastatic colorectal cancer.
Treatment: Systemic treatment (FTD-TPI and bevacizumab) · Radioembolization with 166-Ho microspheres — Extrahepatic disease progression limits clinical efficacy of individualized radioembolization for patients with refractory metastatic colorectal cancer (mCRC). In the same patient population, trifluridine/tipiracil (FTD-TPI) and bevacizumab lead to disease control and overall survival benefit and may be a radiosensitizer. The purpose of this study is to determine safety, tolerability, and activity of individualized radioembolization with 166Holmium (166Ho)-microspheres combined with FTD-TPI and bevacizumab.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
Unresectable liver dominant mCRC; At least one measurable liver lesion according to the PERCIST 1.0
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: fluoropyrimidine — metastatic
Prior therapy with fluoropyrimidine for the treatment of metastatic colorectal cancer and had demonstrated progressive disease or intolerance to their last regimen
Must have received: oxaliplatin — metastatic
Prior therapy with oxaliplatin for the treatment of metastatic colorectal cancer and had demonstrated progressive disease or intolerance to their last regimen
Must have received: irinotecan — metastatic
Prior therapy with irinotecan for the treatment of metastatic colorectal cancer and had demonstrated progressive disease or intolerance to their last regimen
Cannot have received: radioembolization
Previous or current treatment with radioembolization
Cannot have received: chemotherapy
Exception: within 28 days prior to study treatment
Receipt of chemotherapy within 28 days prior to study treatment
Lab requirements
Blood counts
WBC ≥ 3.0 x 10^9/L, platelets ≥ 100 x 10^9/L, absolute neutrophil count > 1.5 x 10^9/L, Hemoglobin (Hb) > 5 mmol/L (>8.1 g/dL)
Kidney function
eGFR ≥ 35 ml/min
Liver function
Serum transaminases (AST & ALT) ≤ 5 x upper limit of normal (ULN), Total bilirubin ≤ ULN, Albumin > 3 g/dL
Adequate organ function as measured by: WBC ≥ 3.0 x 10^9/L, platelets ≥ 100 x 10^9/L, absolute neutrophil count > 1.5 x 10^9/L, Hemoglobin (Hb) > 5 mmol/L (>8.1 g/dL), eGFR ≥ 35 ml/min, Serum transaminases (AST & ALT) ≤ 5 x upper limit of normal (ULN), Total bilirubin ≤ ULN, Albumin > 3 g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06563986 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radioembolization, chemotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages